Pneumonia bacterial

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Phase III: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Evopoint Biosciences USA Inc. Commercial
    (1R,4S)-4-(5-((S)-2-IMINIOIMIDAZOLIDIN-4-YL)-1,3,4- OXADIAZOL-2-YL)-6-OXO-5,7- DIAZASPIRO[BICYCLO[3.2.1]OCTANE-2,1'-CYCLOPROPAN]-7-YL SULFATE; CILASTATIN, IMIPENEM, RELEBACTAM
    2022-501952-27-00 2 countries 2024 n=58
    Ended

Phase IV

1 trial
  • Hospital Clinico San Carlos Academic
    CEFTRIAXONE
    2025-521454-42-00 1 country n=60
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Evopoint Biosciences USA Inc. Commercial 1 Phase III 0
Hospital Clinico San Carlos Academic 1 Phase IV 0
New trials by year
2024
1
← All indication landscapes